ReGen Biologics announced that the official US product launch of its Menaflex collagen scaffold device will take place at the American Academy of Orthopaedic Surgeons (“AAOS”) annual meeting February 25-28, 2009 in Las Vegas. The Menaflex device received FDA clearance in mid-December 2008. ReGen plans to highlight the Menaflex device at the AAOS in the technical exhibit hall with product demonstrations and informational activities. Jeff Chandler, ReGen’s Senior Vice President, Sales and Marketing will lead the launch. “We are delighted that Jeff has joined the ReGen management team. He has an excellent perspective on the opportunity for this ‘first of its kind’ meniscus product and the leadership required for it to become an important option in the standard of care for meniscus treatment,” said Gerald E. Bisbee, Jr., Ph.D., ReGen’s Chairman and CEO. ReGen places a high priority on training and education of surgeons, to provide initial and follow-up training on the Menaflex surgical procedure and appropriate indications for the use of the device in the treatment of meniscus injuries. The first session for US surgeon trainers is taking place in Innsbruck, Austria January 12-13, 2009, where surgeons have been performing the Menaflex surgery for several years. Two prominent European sports medicine surgeons are leading the two-day training session.